Clinical Trial Search

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145

Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Prepulse Inhibition (PPI) — 22.629; 41.162; 50.626; 50.626 % inhibition of startle

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Positive and Negative Syndrome Scale (PANSS) — 72.9 score on a scale

Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05

Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks — -26.6; -23.7; -27.0 units on a scale — p=0.05

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01

Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053

Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001

Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale

Primary: The State Social Paranoia Scale (SSPS) — 9.72; 3.90 The change score of SSPS (pre - post) — p=0.023

Primary: Emotion Recognition as Measured by the Emotion Recognition-40 at the 6 Week Time Point — 7.25; 6.67; 4.38; 6.17 number of correct responses — p=.61

Primary: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores (Cohorts 1 and 2) at Day 10 — -0.2; -0.3; 0.1; 0.0 Units on a scale

Primary: UCSD Performance-based Skills Assessment Total Score (Measures Functional Capacity) — 82.7; 84.4 units on a scale

Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02

Primary: Time to Relapse of Psychotic Symptoms During 6 Weeks — 23.8; 16.9; 17.3 days

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale